Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company focused on novel therapies for serious rare and ultra-rare genetic diseases. The RARE news feed highlights company announcements on commercial performance, clinical development, and key corporate decisions that shape its rare disease portfolio.
Investors and followers of Ultragenyx can find updates on revenue trends from its approved products Crysvita, Dojolvi, Mepsevii, and Evkeeza in select territories, as well as guidance ranges and commentary on operating expenses and cash position. Earnings-related press releases and Form 8-K summaries detail product sales, royalty revenue, and royalty financing transactions, including agreements involving future Crysvita royalties with OMERS.
The news stream also covers Ultragenyx’s late-stage pipeline and regulatory milestones. Readers can track progress of AAV gene therapy programs such as DTX401 for glycogen storage disease type Ia, UX111 for Sanfilippo syndrome type A, and UX701 for Wilson disease, along with monoclonal antibody UX143 for osteogenesis imperfecta and antisense oligonucleotide GTX-102 for Angelman syndrome. Company releases describe Phase 3 study results, longer-term follow-up data, regulatory designations, rolling BLA submissions, and responses to FDA communications such as Complete Response Letters.
In addition, the RARE news page features items on conference presentations, investor events, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). By reviewing these updates, users can follow how Ultragenyx manages its commercial portfolio, advances its clinical pipeline, and executes financing and collaboration strategies in the rare and ultra-rare disease space.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced impressive long-term data from Phase 1/2 trials at the ICIEM. For DTX401 in Glycogen Storage Disease Type Ia, mean daily cornstarch intake reduction reached 69.9%, with significant glucose control improvements observed over three years. DTX301 for Ornithine Transcarbamylase deficiency demonstrated durable metabolic stability, with responders stable up to four years post-treatment. Notably, no major adverse events were reported, signaling potential for enhanced patient quality of life.
Ultragenyx Pharmaceutical reported Q3 2021 revenues of $81.6 million, driven by $50.3 million from Crysvita, marking a 35% year-over-year increase. The company anticipates total Crysvita revenue for the year at the higher end of $180 million to $190 million. Dojolvi revenue surged by 176% to $10.7 million. However, operating expenses rose to $171.5 million, a 30% increase due to pipeline advancements, leading to a net loss of $73 million. Ultragenyx is poised for multiple clinical study initiations, aiming to expand its innovative therapies for rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) plans to host a conference call on November 2, 2021, at 5 PM ET, to discuss its financial results and corporate update for Q3 2021. The live call can be accessed by phone or via webcast through the company's website. Ultragenyx focuses on developing therapies for rare genetic diseases and has established a diverse portfolio of approved medicines. The company emphasizes efficient drug development to meet urgent patient needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Jefferies Gene Therapy/Editing Summit on October 28, 2021, at 3:30 PM ET. The presentation will focus on the company's commitment to developing therapies for rare and ultra-rare genetic diseases. A live and archived webcast of the event will be available on Ultragenyx's website, with replays accessible for 90 days. The company prioritizes efficient drug development to meet the urgent needs of patients lacking effective treatment options.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the successful screening and enrollment of patients for its pivotal Phase 1/2/3 study of UX701, an innovative gene therapy for treating Wilson disease. This seamless study design will evaluate the therapy's safety and efficacy in patients currently receiving standard care. Following a structured 52-week period, primary efficacy endpoints include changes in urinary copper concentration and reductions in standard care medication. UX701 aims to address significant unmet needs in a condition affecting over 50,000 individuals in developed countries.
The first patient has been dosed in a Phase 1/2 study for GTX-102, targeting Angelman syndrome, by GeneTx and Ultragenyx (NASDAQ: RARE). The study involves multiple-dose, dose-escalating administration to evaluate safety and efficacy across various patient domains. Preliminary updates will be available by year-end, with complete data expected in mid-2022. GTX-102 aims to reactivate the paternal UBE3A allele, potentially improving neurological symptoms. The study design includes specific dosing for different age cohorts, based on prior successful trials.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of non-qualified stock options for 8,620 shares and 2,880 restricted stock units to a newly hired non-executive officer. This award, approved by the company's compensation committee, is part of the Ultragenyx Employment Inducement Plan, effective October 1, 2021. The stock options have a ten-year term with an exercise price of $87.80, equal to the stock's closing price on the grant date. The restricted stock units vest over four years, promoting long-term employment alignment.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that new data on Crysvita® for X-linked hypophosphatemia (XLH) and UX143 (setrusumab) for osteogenesis imperfecta (OI) will be presented at the ASBMR 2021 Annual Meeting from October 1-4 in San Diego. Key presentations include oral sessions on neurological manifestations of XLH and the Phase 2b ASTEROID study results for setrusumab. The conference will also feature real-time virtual access. Crysvita is indicated for treating XLH in patients aged six months and older, showcasing significant advancements in rare disease therapies.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the FDA's removal of the clinical hold on GTX-102, an experimental treatment for Angelman syndrome. This allows GeneTx to commence dosing naïve pediatric patients in a Phase 1/2 study. The trial aims to evaluate the drug's safety and effectiveness, enrolling eight patients aged 4 to 8 years in the U.S. The therapy targets the UBE3A gene, which is crucial for brain function and is absent in individuals with Angelman syndrome. There are currently no approved treatments for this condition.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021, at 4:15 PM ET. The presentation will be available via a live and archived webcast on the company’s website, with the replay accessible for 90 days. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, emphasizing novel products with high unmet medical needs. The company aims for efficient drug development to deliver urgent solutions to patients.